AmbioPharm is no longer offering generic peptides. Our focus is on peptide NCEs (new chemical entities).

AmbioPharm, one of the world’s largest capacity peptide development and manufacturing companies, is a peptide Active Pharmaceutical Ingredients (APIs) manufacturer.

With our USA headquarters located in North Augusta, South Carolina and two facilities in Shanghai, China, we manufacture new chemical entities under cGMP regulations for clients worldwide.

The US Food & Drug Administration (FDA) performs Pre-Approval Inspections (PAIs) and Regular Inspections of our facilities (both US and China) under the Federal Food, Drug, and Cosmetic Act (FD&C Act). 

We specialize in developing highly efficient manufacturing processes for peptide-based APIs from small to large scales and are a quality-focused CDMO.